The invention refers to a composition and a method for regulating the activity of a surface growth factor receptor. In a sense, the compound provided by the invention has the effect of inhibiting EGFR. 5 in the first realization, a compound of formula (1) is provided here,A plasma, or a pharmaceutically acceptable salt: (1) ring a is a 6-10 member single or double ring arilo； a 5-10 member heteromorph consisting of 1-4 non normal atoms selected from n, 10 or S, Or a single or double ring heteromorphism, consisting of 4-12 members, consisting of 1-4 heteroatoms selected from n, O and s, which can be replaced by Oxo； ring B is phenyl； heteromorphism composed of 5-6 members, consisting of 1-3 heteroatoms selected from n, O and S； or heteromorphism composed of 5-6 members, consisting of 1-2 heteroatoms. Select from n, O and s, and choose to replace 15 with oxo； E is NH or CH2； R1,R1 'and R2 are independent hydrogen； halogen； cyanogen； C1-6 tar； C1-6 halogen tar, which is composed of 5-6 heteroatoms, including 1-4 heteroatoms selected from n, O and S； phenyl, 5-6 isomerization atoms, including 1-2 heteroatoms selected from n, s and P, which can be replaced by Oxo； x120-c (o) or3； -X1-OC（o）R3，X1-C（o）R3-；-X1-C（o）NR4R5；-X1-C（o）NR4-X3-C（o）Or3；-X1-C（o）NR4-X3-S（o）0-2 R6；-X1-NR4R5；-X1N4-X2-C（o）R3；-X1-NR4-X2-C（o）Or3；-La invención se refiere a composiciones y métodos para modular la actividad del receptor del factor de crecimiento epidérmico (EGFR). En un aspecto, la invención proporciona compuestos que actúan como inhibidores de EGFR. 5 En una primera realización, se proporciona en la presente un compuesto de la Fórmula (1), un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo: (1) en donde el Anillo A es un arilo monocíclico o bicíclico de 6- 10 miembros； un heteroarilo de 5- 10 miembros que comprende 1- 4 heteroátomos seleccionados entre N, 10 O y S, o un heterociclilo monocíclico o bicíclico de 4- 12 miembros que comprende 1- 4 heteroátomos seleccionados en
